tirzepatide for addiction Emerging evidence continues to expand our understanding of GLP-1 receptor agonists beyond metabolic health. A recent study in adults with obesity who consumed alcohol found that patients receiving Semaglutide or reported GLP-1 drugs for addiction: Confidence

A larger February 2025 study analyzing 37.1 million adults with diabetes across 14 databases found semaglutide users had more than 4 times greater risk of NAION compared to non-GLP-1 drugs, with an incidence rate ratio of 1.32

In accordance with the most current heart disease and stroke statistics published by the American Heart Association, it is estimated that more than 100 million people in the USA, which is equivalent to more than 50% of all people over the age of 18, have hypertension

Publication date: Sept

Flow rate and injection time Needle gauge affects the flow rate of the medication during injection

Self-adjusting doses or skipping guidance increases risk without improving results